热门资讯> 正文
TG Therapeutics宣布1亿美元股票回购计划
2025-09-04 01:40
- TG Therapeutics (NASDAQ:TGTX) announced on Wednesday that its board authorized a new share repurchase program to buy back shares worth up to $100M from time to time through open-market purchases and other transactions.
- The program highlights its resolve to generate value for its shareholders and indicates management’s view that TGTX stock doesn’t adequately reflect the “multibillion-dollar potential” of its lead asset, Briumvi, or the company’s long-term prospects, the biotech said.
- The announcement coincided with the completion of TG’s (NASDAQ:TGTX) previously authorized $100M share buyback program, under which the company has repurchased nearly 3.5M shares at $28.55 per share on average since its launch in August 2024.
- CEO Michael Weiss added that during the month of August alone, the company could buy back roughly $78M worth of TGTX shares at attractive prices.
More on TG Therapeutics
- TG Therapeutics: Looking For The Stimulus For A Turnaround
- TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
- The Play On TG Therapeutics
- TG Therapeutics falls after Q2 miss despite guidance raise
- TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
